Table 2. Summary of the clinical... | American Society of Hematology

Table 2.

Summary of the clinical outcomes of study participants (N = 211)

Outcome	Event time	Count	Tac/Sir	Tac/Mtx	P value*
Acute GVHD grade 2-4	Never	141	71	70	.73
	By day 28	22	14	8
	After day 28	48	19	29
Chronic GVHD†	Never	76	32	44	.09
	By day 100	4	3	1
	After day 100	131	69	62
	After day 180	95	51	44
	After day 365	19	10	9
	After day 730	1	0	1
NRM	Never	188	91	97	.46
	By day 28	0	0	0
	After day 28	23	13	10
	After day 100	23	13	10
	After day 180	20	11	9
	After day 365	9	5	4
	After day 730	1	0	1
Survival status by 2 y (day 730)	Yes (alive)	157	76	81	.57*
	No (dead)	54	28	26
Relapse/progression	Never	159	80	79	.57
	By day 28	1	1	0
	After day 28	51	23	28
	After day 100	42	20	22
	After day 180	27	14	13
	After day 365	12	7	5
	After day 730	0	0	0
VOD/SOS	Never	197	94	103	.08
	By day 28	6	4	2
	After day 28	8	6	2
Total no. of patients	Biomarker data available	211	104	107

Outcome	Event time	Count	Tac/Sir	Tac/Mtx	P value*
Acute GVHD grade 2-4	Never	141	71	70	.73
	By day 28	22	14	8
	After day 28	48	19	29
Chronic GVHD†	Never	76	32	44	.09
	By day 100	4	3	1
	After day 100	131	69	62
	After day 180	95	51	44
	After day 365	19	10	9
	After day 730	1	0	1
NRM	Never	188	91	97	.46
	By day 28	0	0	0
	After day 28	23	13	10
	After day 100	23	13	10
	After day 180	20	11	9
	After day 365	9	5	4
	After day 730	1	0	1
Survival status by 2 y (day 730)	Yes (alive)	157	76	81	.57*
	No (dead)	54	28	26
Relapse/progression	Never	159	80	79	.57
	By day 28	1	1	0
	After day 28	51	23	28
	After day 100	42	20	22
	After day 180	27	14	13
	After day 365	12	7	5
	After day 730	0	0	0
VOD/SOS	Never	197	94	103	.08
	By day 28	6	4	2
	After day 28	8	6	2
Total no. of patients	Biomarker data available	211	104	107

P value from Gray’s test for the cumulative incidence of the outcome, except for OS where the P value is from a log-rank test.

Incidence of chronic GVHD was slightly higher in this study compared with the original BMT CTN 0402 study (64% vs 49%).